Kleinostheim, Germany, 18th November 2010 – curasan AG, listed in the
General Standard (ISIN: DE 000 549 453 8) has received the certification for
the synthetic bone regeneration material Cerasorb® M ORTHO from the
Canadian authorities, Health Canada.
“This news has come as a pleasant surprise”, stated Hans Dieter Rössler,
CEO. “Since the approval process for medical devices by the Canadian
authorities is highly demanding, we were actually expecting the certification
some time next year.”
Cerasorb® M ORTHO is now approved for sales in the whole of North America.
Furthermore, curasan AG considers that the experience gained with the
authorities in Canada will be useful and beneficial for other product approvals in
this market. This is a significant development for potential sales partners since
further new bio materials are expected to be available earlier for market launch.
Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the
field of regenerative medicine especially in bone and tissue regeneration. In addition to
the synthetic Cerasorb® bone substitution and regeneration material, the company has
developed a future-oriented product pipeline. The goal during the next few years is to
have further medical products ready for market rollout via well-positioned contractual
partners in various market segments.
Tel. +49 (0)6027 40 900-51
Fax +49 (0)6027 40 900-39
fr financial relations gmbh
Tel. +49 (0)69 95 90 83 20
Fax +49 (0)69 95 90 83 99